Journal List > J Korean Assoc Oral Maxillofac Surg > v.36(1) > 1032372

Kim, Han, and Roh: Stromal cell-derived factor-1 (SDF-1) expression in the oral squamous cell carcinoma

Abstract

Purpose

Chemokines are structurally related, small polypeptide signaling molecules that bind to and activate a family of transmembrane G protein-coupled receptors, the chemokine receptors. Recently, interaction between the chemokine receptor CXCR4 and its ligand, stromal cell-derived factor 1 (SDF-1 or CXCL12), has been found to play an important role in tumorigenicity, proliferation, metastasis and angiogenesis in many cancers such as lung cancer, breast cancer, melanoma, glioblastoma, pancreatic cancer and cholangiocarcinoma.
Hence, the goal of this study is to identify the correlation of clinicopathological factors and the up-regulation of SDF-1 expression in oral squamous cell carcinoma.

Material and methods

We studied the immunohistochemical staining of SDF-1, quantitative RT-PCR (qRT-PCR) of SDF-1 gene in 20 specimens of 20 patients with oral squamous cell carcinoma.

Results

1. In the immunohistochemical study of poor differentiated and invasive oral squamous cell carcinoma, the high level staining of SDF-1 was observed. And the correlation between immunohistochemical SDF-1 expression and tumor nodes metastases (TNM) classification of specimens was significant.(x2 test, P < 0.05)
2. In the SDF-1 gene qRT-PCR analysis, SDF-1 expression was more in tumor tissue than in carcinoma in situ tissue. Paired-samples analysis determined the difference of SDF-1 mRNA expression level between the cancer tissue and the carcinoma in situ tissue.(Student's t-test, P < 0.05)

Conclusion

These findings suggest that up-regulation of the SDF-1 may play a role in progression and invasion of oral squamous cell carcinoma.

References

1. Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res. 1998; 18:4779–86.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94:153–6.
crossref
3. Carvalho AL, Ikeda MK, Magrin J, Kowalski LP. Trends of oral and oropharyngeal cancer survival over five decades in 3267 patients treated in a single institution. Oral Oncol. 2004; 40:71–6.
crossref
4. Pisani P. Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999; 83:18–29.
5. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999; 80:827–41.
6. Carvalho AL, Magrin J, Kowalski LP. Sites of recurrence in oral and oropharyngeal cancers according to the treatment approach. Oral Dis. 2003; 9:112–8.
crossref
7. Hemmer J, Kreidler J. Flow cytometric DNA ploidy analysis of squamous cell carcinoma of the oral cavity. Comparison with clinical staging and histologic grading. Cancer. 1990; 66:317–20.
crossref
8. Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol. 2002; 42:469–99.
crossref
9. Laing KJ, Secombes CJ. Chemokines. Dev Comp Immunol. 2004; 28:443–60.
crossref
10. Murdoch C, Finn A. Chemokine receptors and the role in inflammation and infectious diseases. Blood. 2000; 95:3032–43.
11. Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Murakami K, Miyake Y, et al. CXCL12 and CXCR4 expression by human gingival fibroblasts in periodontal disease. Clin Exp Immunol. 2005; 141:467–74.
crossref
12. Rossi D. Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000; 18:217–42.
13. Mu ¨ller A, Homey B, Soto H, Ge N, Catron D, Buchanan M, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410:50–6.
crossref
14. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002; 62:1832–7.
15. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res. 2001; 61:4961–5.
16. Uchida D, Begum NM, Almofti A, Nakashiro K, Kawamata H, Tateishi Y, et al. Possible role for stromal-cell-derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. Exp Cell Res. 2003; 290:289–302.
17. Bertolini F, Dell’ Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S, et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin’ s lymphoma. Cancer Res. 2002; 62:3106–12.
18. Murakami T, Maki W, Cardones AR, Fang H, Tun Kyi A, Nestle FO. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 2002; 62:7328–34.
19. Ghadjar P, Coupland SE, Na IK, Noutsias M, Letsch A, Stroux A, et al. Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol. 2006; 24:1910–6.
crossref
20. Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel RE, Jiang WG. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Research. 2005; 7:R402–10.
crossref
21. Daly AJ, McIlreavey L, Irwin CR. Regulation of HGF and SDF-1 expression by oral fibroblasts-implications for invasion of oral cancer. Oral Oncol. 2008; 44:646–51.
22. Kim H, Muller WJ. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res. 1999; 253:78–87.
crossref
23. Youngs SJ, Ali SA, Taub DD, Rees RC. Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer. 1997; 71:257–66.
crossref
24. Hill MW, Mackenzie IC. The influence of differing connective tissue substrates on the maintenance of adult stratified squamous epithelia. Cell Tissue Res. 1984; 237:473–8.
crossref
25. Mirshahi F. Pourtau J, Li H, Muraine M, Trochon V, Legrand E, et al. SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models. Thromb Res. 2000; 99:587–94.
26. Molino M, Woolkalis MJ, Prevost N, Pratico ′D, Barnathan ES, Taraboletti G, et al. CXCR4 on human endothelial cells can serve as both a mediator of biological responses and as a receptor for HIV-2. Biochim Biophys Acta. 2000; 1500:227–40.
crossref
27. Yang SX, Chen JH, Jiang XF, Wang QL, Chen ZQ, Zhao W, et al. Activation of chemokine receptor CXCR4 in malignant glioma cells promotes the production of vascular endothelial growth factor. Biochem Biophys Res Commun. 2005; 335:523–8.
crossref
28. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999; 13:2905–27.
crossref
29. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001; 411:342–8.
crossref
30. Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M, Yamamoto N. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother. 2006; 60:273–6.
31. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer. 2006; 42:768–78.
crossref

Fig. 1.
Immunohistochemical staining for SDF-1 of normal oral tissue.(×400)
jkaoms-36-1f1.tif
Fig. 2.
Immunohistochemical staining for SDF-1 of oral carcinoma in situ.(×400)
jkaoms-36-1f2.tif
Fig. 3.
Immunohistochemical staining for SDF-1 of moderate differentiated oral squamous cell carcinoma.(×400)
jkaoms-36-1f3.tif
Fig. 4.
Immunohistochemical staining for SDF-1 of poor differentiated and invasive oral squamous cell carcinoma.(×400) (SDF-1: stromal cell-derived factor-1)
jkaoms-36-1f4.tif
Table 1.
The correlation between immunohistochemica SDF-1 expression and clinical and pathological factors.
Variable Case (n) SDF-1 positive expression
n (%) x2 P
Sex
Male 11 5 (45.5%) 0.303 0.582
Female 9 3 (33.3%)
Age
60 ≤ 5 1 (20.0%) 1.111 0.292
60 > 15 7 (46.7%)
Histological differentiation
Well 13 4 (30.8%) 1.319 0.251
Moderate/Poor 7 4 (57.1%)
Tumor size
T1/T2 11 2 (18.2%) 4.848 0.028*
T3/T4 9 6 (66.7%)
Nodal status
N (-) 11 2 (18.2%) 4.848 0.028*
N (+) 9 6 (66.7%)
Metastasis
M (-) 17 5 (29.4%) 5.294 0.021*
M (+) 3 3 (100%)
TNM stage
I/II 8 1 (12.5%) 4.201 0.040*
III/IV 12 7 (58.3%)

n = number of patients, P = P value * x

2 test, significance P < 0.05 (SDF-1: stromal cell-derived factor-1)

Table 2.
Relationship between relative levels of SDF-1 mRNA (SDF-1/GAPDH) and clinical and pathological factors.
Variables No. SDF-1 mRNAa (mean ± SD) P value
Sex
Male 11 1.3822 ± 0.2202 0.37
Female 9 1.2422 ± 0.2934
Stage
I-II 8 1.2050 ± 0.2290 0.302
III-IV 12 1.2163 ± 0.2637
Tumor status
T1 11 1.1978 ± 0.1900 0.249
T2-4 9 1.3622 ± 0.3307
Lymph node status
N0 11 1.2356 ± 0.2330 0.155
N1-3 9 1.3944 ± 0.3956
Metastasis status
M0 17 1.1833 ± 0.1418 0.927
M1 3 1.5433 ± 0.1594
Tissue
Oral squamous CA 20 1.2855 ± 0.2742 0.000*
Carcinoma in situ 20 0.2440 ± 0.1277

a: SDF-1 mRNA expression derived from real-time quantitative RT-PCR * P value derived from Student’ s t test (GAPDH: glyceraldehyde-3-phosphate dehydrogenase)

TOOLS
Similar articles